Nuvation Bio Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Shows how companies protect shareholders from dilution when investors convert debt to stock.
Company borrowed money at low interest that can convert to stock, affecting how much shareholders own.
Documents the details of a major debt offering so investors understand the terms before buying.
Tells investors the official terms of a debt offering that can convert to company stock.
Shows that 83.6% of shareholders participated, giving the company approval to proceed with decisions.
Tells investors how much money the company made or lost and how it's spending in the first quarter.
Details the company's financial position, cash, expenses, and business activities every three months.
Stocky reads Nuvation Bio Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Nuvation Bio Inc.'s most recent tracked filing was a 8-K on 6 Jul 2026: Company completes convertible note offering with capped call protection.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.